Nasdaq exas.
Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...
Direct. 3,000. $16.52. 42,830. Back to EXAS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ...Stock Market Today: Stocks lower, Nvidia and Tesla slide, Gold retreats from record high. Investors are betting on at least five Fed interest-rate cuts next ...Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stockExact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Shares of Exact Sciences (EXAS) have gained 22.9% over the past four weeks to close the last trading session at $43.09, but there could still be a solid upside left in the stock if short-term ...Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ...EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...
(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of ...
Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...
Oct 9, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...
"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...
Fintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Nov 20, 2023 · Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Feb 21, 2023 · Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ... At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new October 28th contracts and identified one put and one call contract of particular ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Nov 30, 2023 · Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...
Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.WebExact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Kevin Conroy, Chairman & CEO ...The company is scheduled to release Q3 earnings on November 3, 2022, after the market close. The market expects revenue of $503 million, a modest 10% YoY growth forecast. As EXAS starts shifting ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The ...EXAS U.S.: Nasdaq Exact Sciences Corp. Watch list NEW Set a price target alert Open Last Updated: Nov 20, 2023 2:33 p.m. EST Real time quote $ 67.73 1.43 2.15% Previous …Web
EXACT SCIENCES CORP ( EXAS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.WebAs of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The average price target represents an increase of ...EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...Exact Sciences Corporation’s EXAS legacy Screening business is witnessing significant improvement, buoyed by Cologuard volume growth. However, escalating costs and stiff competition are concerning.Share $67.49 Nov 29, 10:10:29 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Apple Inc $191.11 AAPL0.37% Pacific Biosciences of California Inc $8.85 PACB2.55% Amazon.com Inc $147.18... A Look At The Intrinsic Value Of Exact Sciences Corporation (NASDAQ:EXAS) (Simply Wall St.) Jul-10-23 08:21AM Top 5 Non-Tech Nasdaq Winners of 1H With More Upside Left (Zacks) 06:00AM Exact Sciences schedules second quarter 2023 earnings call (PR Newswire) Jul-04-23 10:40AM ...Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.
As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.
On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...
According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...In trading on Thursday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $123.15, changing hands as low as $122.60 per share. EXACT Sciences Corp. shares ...EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...EXAS is in a good position to continue its growth. Acquisitions seem to have unlocked new value. ... (NASDAQ: EXAS) as a "buy" at a 1-year price target of $150 (+13% upside) with a strong further ...In summary, the author projects Exact Sciences Corporation (NASDAQ: EXAS) as a "buy" at a 1-year price target of $150 (+13% upside) with a strong further upside through 2023.1. Exact Sciences Corp. (EXAS) In 2023, it is Exact Sciences that is the largest holding in Cathie Wood’s ARKK flagship ETF, and not Tesla. It is 9.7% of the portfolio. Exact Sciences has been ...EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on Supercharts. Overview . News . Ideas Financials Technicals Forecast . EXAS news flow. News didn't load. Looks like that didn't go very well. Let's try again.Exact Sciences' sales will top $2 billion this year as the business continues to achieve impressive growth. ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03.Nov 2, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. ... Exact Sciences (EXAS 4.73%) Q3 2023 Earnings Call Nov 01, 2023, 5:00 p.m. ET. Contents:
The first of my AI stock recommendations is Exact Sciences (NASDAQ: EXAS).Maybe the chatbot knew that Cathie Wood likes the stock.But even if it didn’t, biotechnology (biotech) stocks are a good ...Education. You are performing scenario analysis on Exact Sciences Corp. (NASDAQ: EXAS). You know the Food and Drug Administration's (FDA) Advisory Committee will release their report soon, which provides a recommendation as to whether the company's new colon cancer diagnostics test, Cologuard, should be approved by the …Exact Sciences EXAS stock price today per share is 67.03 USD. How to purchase Exact Sciences stock? You can buy EXAS shares on the NasdaqCM exchange. Contact ...Instagram:https://instagram. how to read candlestick patternslandstar systemshow much is a house surveywhat is the best automated crypto trading platform Fintel reports that on May 5, 2023, UBS initiated coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 18.36% Upside. As of April 24, 2023, the ...MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. real estate hedge fundsarct 3 Nov 2023 ... Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square. ultra wealthy Nov 30, 2023The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.Web